Success of NicOx glaucoma candidates welcome news for Pfizer

Article

Nitric oxide-donating derivatives of latanoprost for the treatment of glaucoma have been shown to successfully lower intraocular pressure (IOP) in preclinical studies.

Nitric oxide-donating derivatives of latanoprost for the treatment of glaucoma have been shown to successfully lower intraocular pressure (IOP) in preclinical studies.

The compounds, which are the result of a collaboration between NicOx and Pfizer in 2004, brought about a greater IOP lowering effect than latanoprost in two validated experimental models of raised IOP. In one of these models, a single topical 0.1% dose of latanoprost resulted in an 18% reduction of IOP compared with a 30% reduction achieved with an equimolar dose of the alternative compound.

The two companies have since signed a second agreement which grants Pfizer exclusive rights to apply NicOx' proprietary nitric oxide-donating technology across the field of ophthalmology.

Related Videos
Ms Neeru Vallabh on a virtual call with Ophthalmology Times Europe
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
© 2024 MJH Life Sciences

All rights reserved.